2024 IDSA Recommendation for Pemivibart
2025 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas now recommend pemivibart for pre-exposure prophylaxis of COVID-19 for moderately to severely immunocompromised individuals3
IDSA, Infectious Diseases Society of America; NCCN, National Comprehensive Cancer Network.
References: 1.Data on file. Invivyd, Inc. New Haven, CT. 2.PEMGARDA Fact Sheet for healthcare providers. Waltham, MA; Invivyd, Inc. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas Version 3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 18, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
IDSA Guidelines recommend pemivibart in moderately or severely immunocompromised individuals 12 years or older at risk for progression to severe COVID-19. The IDSA guideline panel suggests pre-exposure prophylaxis with pemivibart when predominant regional variants are susceptible to the agent (conditional recommendation, low certainty of evidence).
This recommendation is endorsed by the Society of Critical Care Medicine (SCCM), the Society for Healthcare Epidemiology of America (SHEA), the Society of Infectious Diseases Pharmacists (SIDP), and the Pediatric Infectious Diseases Society (PIDS).
Reference: Infectious Disease Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. May 30, 2025. Updated June 04, 2025. Accessed August 19, 2025. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#null
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell lymphomas now recommend pemivibart for pre-exposure prophylaxis of COVID-19 for moderately to severely immunocompromised individuals.
Reference: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 18, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.